{"name":"Xeris Pharmaceuticals","slug":"xeris","ticker":"XERS","exchange":"NASDAQ","domain":"xerispharma.com","description":"Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.","hq":"Chicago, IL","founded":0,"employees":"435","ceo":"Paul R. Edick","sector":"Diabetes / Endocrinology","stockPrice":6.33,"stockChange":-0.1,"stockChangePercent":-1.56,"marketCap":"$1.1B","metrics":{"revenue":195000000,"revenueGrowth":38.3,"grossMargin":85.9,"rdSpend":20921000,"netIncome":-91140000,"cash":111750000,"dividendYield":0,"peRatio":90.4,"fiscalYear":"FY2018"},"revenueBreakdown":[],"timeline":[{"date":"1960-01-01","label":"Glucagen first approved","drug":"Glucagen","drugSlug":"glucagon","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2036-02-16","label":"Glucagen patent expiry (Formulation)","drug":"Glucagen","drugSlug":"glucagon","type":"patent_expiry","sentiment":"negative"},{"date":"2036-02-16","label":"Glucagen patent expiry (Formulation)","drug":"Glucagen","drugSlug":"glucagon","type":"patent_expiry","sentiment":"negative"},{"date":"2039-09-23","label":"Glucagen patent expiry (Formulation)","drug":"Glucagen","drugSlug":"glucagon","type":"patent_expiry","sentiment":"negative"},{"date":"2030-06-01","label":"Gvoke patent cliff ($100M at risk)","drug":"Gvoke","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Glugaon RTU Injection Without Insulin Pump Reduction","genericName":"Glugaon RTU Injection Without Insulin Pump Reduction","slug":"glugaon-rtu-injection-without-insulin-pump-reduction","indication":"Other","status":"phase_2"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Glucagen","genericName":"GLUCAGON","slug":"glucagon","indication":"Gastrointestinal Radiography Adjunct","status":"marketed"}]}],"pipeline":[{"name":"Glugaon RTU Injection Without Insulin Pump Reduction","genericName":"Glugaon RTU Injection Without Insulin Pump Reduction","slug":"glugaon-rtu-injection-without-insulin-pump-reduction","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Glucagen","genericName":"GLUCAGON","slug":"glucagon","phase":"marketed","mechanism":"Glucagen works by stimulating the release of glucose from stored energy sources in the body.","indications":["Gastrointestinal Radiography Adjunct","Hypoglycemic disorder","Severe hypoglycaemia in patients with diabetes"],"catalyst":""}],"recentEvents":[{"date":"2024-03-14","type":"regulatory","headline":"Xeris Pharmaceuticals Announces FDA Approval of Gvoke HypoPen","summary":"Xeris Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved Gvoke HypoPen, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia.","drugName":"Gvoke","sentiment":"positive"},{"date":"2023-11-07","type":"earnings","headline":"Xeris Pharmaceuticals Reports Third Quarter 2023 Financial Results","summary":"Xeris Pharmaceuticals reported its third quarter 2023 financial results, with revenue of $13.4 million and a net loss of $24.9 million.","drugName":"","sentiment":"neutral"},{"date":"2023-08-01","type":"deal","headline":"Xeris Pharmaceuticals Announces Collaboration with Sanofi to Develop and Commercialize Gvoke","summary":"Xeris Pharmaceuticals announced a collaboration with Sanofi to develop and commercialize Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-09","type":"earnings","source":"simplywall.st","summary":"Assessing Xeris Biopharma Holdings (XERS) Valuation After Profitability Milestone And 2026 Revenue Guidance - simplywall.st","headline":"Assessing Xeris Biopharma Holdings (XERS) Valuation After Profitability Milestone And 2026 Revenue Guidance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQWmdEV2lMaDlQcGJXb3AyZnFnbmFyZU1ya251eU13UVdhTjQzSEIzdk16MF9iSlpNT3JrYXREUzd2Q1ptaWVEcllnMm41VHZhX1M4bFRVZ25vYW14cERDc1dwNy0xei1fd3prOVdodGZyeTljRGk0c0l5YzFDVjVlb214SDBDbzdRMHhuaWJpSi1uQXdFcjJBV0pKMnprZTFvUVN0cHUwWGtIUkplYnJz?oc=5","date":"2026-03-04","type":"pipeline","source":"Seeking Alpha","summary":"Xeris Biopharma: Undervalued Given The Potential Of Its Drug Portfolio (NASDAQ:XERS) - Seeking Alpha","headline":"Xeris Biopharma: Undervalued Given The Potential Of Its Drug Portfolio (NASDAQ:XERS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNVkhFa2IxZGFhMXh4bmlBalQ2UjN5Q0ZoR29kZ3lZQ0FUNGF2WlFNUGpUUzM2VTVtTlNXUDZrQ01LLU1rSFdmZlR1ZGFpSEw0aGtOU1JYTjNTZkdXR2dROEFRR1JLNE9RaTB3MVk1M0RGU0MzWG9mZk9BVXZGa1dXMkNjeVVNRG0xZ0pQMng2dUhvcFo1ZlpTblh0eEF6cGx3cGpOQWVZNVBZbTd6MHc?oc=5","date":"2026-02-27","type":"pipeline","source":"Benzinga","summary":"Why Are Shares Of Xeris Biopharma Falling Friday? - Benzinga","headline":"Why Are Shares Of Xeris Biopharma Falling Friday?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxQeGVib3BIaWVwb1ctcUJiOU9WbHdSLTRBa2hjLXZzSkl0VXFaVFZPRmlrMzJqUTFsb1I2MjBhMVhaRHREcVo1SDk0b0FZTFdYT3hucmJfNUFzd2EyU3hod3NMSzVzRG1PbU1icGZQdng2WGl2UDA0cW5VYU03Smh4SmwzMDV0NHdGcUJPMWZoX05DU2lFN3E3MTlrc2RBLWcxX1N6SE52ZDJycGV4ZDNtRHFvNDV3Wi1uQmxGLVBzbXZETU1uMnc?oc=5","date":"2026-02-26","type":"patent","source":"Business Wire","summary":"Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit - Business Wire","headline":"Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxPblVkY05ZZDM0b0I0RldBYmZDM0tua0F1VWh3ZVNvLVZidXgzcFpJOXZYVGJvVmJXRFRpSHBTbUZBZVVYS2tJS3loNDlwS18xV0R3SnBselFhelZVeE94bXpiTzhKZDB4UkRQQnFkTnprdlByQTk5QTlJc0hjREFqUnFSWEVvbm9Fdm5QaGZUcEgxc2o3Y25DMlZPbmREb3FTSmQ4d3Zva1dCX0g1dkRpR2xIQ2ZZSlAzMm9SMmZ4THhaZXJIby1uR1dPM1I2SDVfenRaem1qa1RScE5rVm04Wnl3N1Q4RGR0T1VOQk84Q0pqekFabDB2VGlicw?oc=5","date":"2026-02-17","type":"pipeline","source":"Business Wire","summary":"Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026 - Business Wire","headline":"Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQb0NmT3hzVmJmT2Z5OGJxTm90N3hfTEdXWk5BeDI1c3ZIcWdJby1DaVRibi03WGFqaFF0SWExTDJCMVVwQXRPZDVaUF9nOVJEeW9KTWlVZGczeGo0a1plNDdON0xZbEtNT2tPblhTREQxLTAxZW5pTHR1SFl1NlhoMDFSNnpvMkRxdmtxMGtXTnV3TzNiM25HMFBhM2VXR0RYTzl4a2NqVEl5QQ?oc=5","date":"2026-02-03","type":"pipeline","source":"Seeking Alpha","summary":"Xeris Biopharma: Strong Recorlev Momentum And Pipeline Opportunity (XERS) - Seeking Alpha","headline":"Xeris Biopharma: Strong Recorlev Momentum And Pipeline Opportunity (XERS)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-10","type":"pipeline","source":"simplywall.st","summary":"Is Xeris Biopharma Holdings (XERS) Price Rally Still Justified After Recent Company Updates - simplywall.st","headline":"Is Xeris Biopharma Holdings (XERS) Price Rally Still Justified After Recent Company Updates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPNU9hM3FOcjllRmpqYVhseUpuY2E0UWN3X01WN3ZuTTlkMC05Ynp6R2NEOVdpVnY3RzY3WjMxVlZRQm9nUzJYajBUbE5sdHhvdlZVMlpueHk1SDVKb0JPRVpMS2lKaHZQXzAzMFB5RUdLUXRYVmJMdVE4aU1wb3VhRnV4X2NpelhGZFFQQ3E3bzF3R0g3MTlTYmhsQW42X3JUMGFxd2dBeHN5MDc1?oc=5","date":"2026-01-05","type":"deal","source":"TheStreet Pro","summary":"This Small Biotech Stock Is Still a Buy After Massive Bottom-Line Gift - TheStreet Pro","headline":"This Small Biotech Stock Is Still a Buy After Massive Bottom-Line Gift","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxPQnRPVDAwcDI0Nk9lbnNfYUNWYzhSUTZNa0QtZFdXa0FKenZhOFVjU2RMMVVscTZKRGMxUmVWaXR0UklkUzRwS1ZVVGprZV8xME4wbG9FOXV4WGU0V2dSYi1vbGVRdXFNbmt6TmF4d1FTVzRMNHZHNFFkenNTcXRwbnVwcmlEY1VSMGZWOC1PT0xPRnV3NkU0LUdSTDM0em5tUGl5UzdxclJQSzZLQ2NWWlBONnFkeEJkM2sydkRyN0VXZHYwS1VTNDctS3F4NkhPelZzdWx3?oc=5","date":"2026-01-02","type":"pipeline","source":"Business Wire","summary":"Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire","headline":"Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxNQTczZ3RjVGdNMEtGV0tuVThBaEtLY29EMnVhNFF0SDBNRnFzbFYyb0pkNk13WVQ2RVg4aWhQVm9XUkRfZXpGcWF5RmNwNU92dDdoTS1OZTVSOUJYM3NkN3NYOUZ3RTBwb0lUSzlLVV9OTDUyUGhmSkh2cjRWUnQwOVdHSmkwdEh4cWZaZ0Y1dWhEQXp0VFdOUjFOcUhVbngtZlBUajhta3VLUFo3RlR4cE5qdmVnTkctU0NzMXBVZUc5ems?oc=5","date":"2025-12-31","type":"regulatory","source":"Investing.com","summary":"Xeris Pharmaceuticals stock rises as rival drug faces FDA setback - Investing.com","headline":"Xeris Pharmaceuticals stock rises as rival drug faces FDA setback","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPZFc5OFN2TEVwWnhLQlZhRFlzMXduWF9UZ0Z5M1h6WWhYT2dYZ0Z2eHRRa1VNaWUzTjRyQm00MFU2ODNFRWNObFZUUFRvUjFCQ1Y2ZHg0djZmUVRyTWpSeVJRYndjcFctQ05fZUhhUnRCRXU2ZGJLN1VZVW1vWE9FVDVFUTJLYXhnREUyeTNCanA3a0Q2QzFlQjJGSGY?oc=5","date":"2025-10-21","type":"pipeline","source":"Seeking Alpha","summary":"Xeris Biopharma Stock: Quality Business At A Premium Valuation (NASDAQ:XERS) - Seeking Alpha","headline":"Xeris Biopharma Stock: Quality Business At A Premium Valuation (NASDAQ:XERS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTFBzUWwxNTVTZXlKVF9sVFZHTXI5eVJzRUk5aHBmM1JValpFNHI3OHM0T3ZYMDJyYk5UZXpfSEF3NVFaTmtRbTFkV2M2OEtfTkp3?oc=5","date":"2024-03-03","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"}],"patents":[{"drugName":"Gvoke","drugSlug":"glucagon","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":100000000},{"drugName":"Glucagen","drugSlug":"glucagon","patentNumber":"10213487","type":"Formulation","expiryDate":"2036-02-16","territory":"US","genericFilings":[]},{"drugName":"Glucagen","drugSlug":"glucagon","patentNumber":"12370241","type":"Formulation","expiryDate":"2036-02-16","territory":"US","genericFilings":[]},{"drugName":"Glucagen","drugSlug":"glucagon","patentNumber":"10765602","type":"Formulation","expiryDate":"2039-09-23","territory":"US","genericFilings":[]}],"drugCount":2,"phaseCounts":{"phase_2":1,"marketed":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Novo Nordisk","Sanofi","Eli Lilly"],"therapeuticFocus":["Diabetes","Endocrinology"],"financials":{"source":"sec_edgar","revenue":100000,"revenuePeriod":"2018-12-31","revenueHistory":[{"value":100000,"period":"2018-12-31"},{"value":16000,"period":"2017-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":20921000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-91140000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":159151000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":6.33,"previousClose":6.43,"fiftyTwoWeekHigh":10.08,"fiftyTwoWeekLow":4.3,"fiftyTwoWeekRange":"4.3 - 10.08","fiftyDayAverage":5.93,"twoHundredDayAverage":7.11,"beta":0.92,"enterpriseValue":1256891392,"forwardPE":15.1,"priceToBook":77.2,"priceToSales":3.47,"enterpriseToRevenue":3.99,"enterpriseToEbitda":26.14,"pegRatio":0,"ebitda":48080000,"ebitdaMargin":15.3,"freeCashflow":42205376,"operatingCashflow":48527000,"totalDebt":258552992,"debtToEquity":1987.2,"currentRatio":2.12,"returnOnAssets":6.3,"returnOnEquity":0,"analystRating":"1.4 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":7,"targetMeanPrice":11.29,"targetHighPrice":18,"targetLowPrice":8,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":3.3,"institutionHeldPercent":53.1,"sharesOutstanding":172642055,"floatShares":163840763,"sharesShort":15894656,"shortRatio":11.1,"shortPercentOfFloat":9.2,"epsTrailing":0.07,"epsForward":0.42,"revenuePerShare":1.91,"bookValue":0.08,"officers":[{"age":63,"name":"Mr. John P. Shannon","title":"CEO & Director"},{"age":61,"name":"Mr. Kevin  McCulloch","title":"President & COO"},{"age":48,"name":"Mr. Steven M. Pieper","title":"Chief Financial Officer"},{"age":61,"name":"Ms. Beth P. Hecht J.D.","title":"Chief Legal Officer & Corporate Secretary"},{"age":50,"name":"Dr. Anh T. Nguyen M.B.A., M.D.","title":"Chief Medical Officer"},{"age":null,"name":"Ms. Allison  Wey","title":"Senior Vice President of Investor Relations & Corporate Communications"},{"age":null,"name":"Mr. Brian  Conner","title":"SVP of Quality and Chief Compliance & Risk Officer"},{"age":null,"name":"Ms. Kendal  Korte","title":"Senior Vice President of Human Resources"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.xerispharma.com","phone":"844 445 5704"}}